Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus
(SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE …

Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …

Objective To evaluate the safety and tolerability of multiple intravenous (IV) doses of
sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE). Methods In …

Objective Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling
without substantial reductions in the number of B cells. The aim of this study was to report …

… markers with an average spacing of 12 cM. Non-parametric multipoint linkage analysis …
The FcγRII locus is within ∼3 cM from the D1S484 marker (24) used in the present study. …

PURPOSE: We assessed the outcome of 31 patients with severe neuropsychiatric (NP)
systemic lupus erythematosus (NPSLE) treated with intravenous cyclophosphamide (IV-CYC), …

Objective To examine associations between active patient–physician communication and
measures of morbidity in patients with systemic lupus erythematosus (SLE). Methods …

… The patient is a 35-year-old-woman with severe neuropsychiatric lupus (further
described in Neuwelt CM, Asherson RA, Daikh DI; [38]) spanning 18 years, with a vaso-occlusive …

… Neuwelt has received consulting fees (less than $10,000 each) from HGS, GSK, and UCB
Pharma. Dr. Houssiau has received consulting fees (less than $10,000) from UCB Pharma. …

OBJECTIVE: Modifiable psychosocial factors that are associated with health outcomes may
provide new opportunities for treatment. We investigated the associations of various …